Cargando…

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review

IMPORTANCE: A thorough understanding of the optimal role and sequence of agents for treatment of multiple myeloma (MM) requires knowledge of the use and rate of postprotocol therapies in randomized clinical trials (RCTs). OBJECTIVES: To examine the proportion of MM RCTs that reported postprotocol th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohyuddin, Ghulam Rehman, Koehn, Kelly, Abdallah, Al-Ola, Goodman, Aaron M., Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082314/ https://www.ncbi.nlm.nih.gov/pubmed/33909053 http://dx.doi.org/10.1001/jamanetworkopen.2021.8084

Ejemplares similares

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma
por: Najjar, Mimi, et al.
Publicado: (2023)

Hospitalization at the end of life in patients with multiple myeloma
por: Abbasi, Saqib, et al.
Publicado: (2021)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020
por: Van Oekelen, Oliver, et al.
Publicado: (2022)

Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019
por: Balmaceda, Nicole, et al.
Publicado: (2021)

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
por: Fatoki, Raleigh Ayoolu, et al.
Publicado: (2022)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
por: Gil, Kellen, et al.
Publicado: (2022)

Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2023)

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
por: Reynolds, Gemma, et al.
Publicado: (2023)

P1518: INFECTIONS FOLLOWING BISPECIFIC ANTIBODIES IN MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Reynolds, Gemma, et al.
Publicado: (2023)

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
por: Benda, Magdalena A., et al.
Publicado: (2023)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2016)

A Rare Presentation of a Rare Disease: Pulmonary Lymphomatoid Granulomatosis
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2012)

Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review
por: Sharp, John, et al.
Publicado: (2021)

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
por: Fonseca, Rafael, et al.
Publicado: (2020)

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China
por: Tang, Wenjiao, et al.
Publicado: (2023)

P978: EVOLVING PATTERNS IN MULTIPLE MYELOMA TREATMENT ATTRITION RATES AND PROGRESSION THROUGH LINES OF THERAPY WITH MODERN CHEMOTHERAPY OPTIONS
por: Al-Kaisi, Firas, et al.
Publicado: (2023)

Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
por: Cowan, Andrew J., et al.
Publicado: (2018)

A Rare Cause of Hemophagocytic Lymphohistiocytosis: Fusobacterium Infection—A Case Report and Review of the Literature
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2016)

Workforce Attrition Among Male and Female Physicians Working in US Academic Hospitals, 2014-2019
por: Chen, Ya-Wen, et al.
Publicado: (2023)

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia
por: Atrash, Shebli, et al.
Publicado: (2017)

Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster
por: Landgren, Ola, et al.
Publicado: (2018)

Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination
por: Abdallah, Al-Ola, et al.
Publicado: (2021)

Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors
por: Jentzsch, Valerie, et al.
Publicado: (2023)

Applying the Principles of Bloom’s Taxonomy to Managing Tachyarrhythmia: Results of a Tachyarrhythmia Workshop
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2019)

Does Use of High-fidelity Simulation Improve Resident Physician Competency and Comfort Identifying and Managing Bradyarrhythmias?
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2020)

P973: ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE
por: More’, Sonia, et al.
Publicado: (2023)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review
por: Banerjee, Rahul, et al.
Publicado: (2021)

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant
por: Rhee, June-Wha, et al.
Publicado: (2023)

Multiple myeloma: challenges with deciding the optimal sequencing strategy
por: Walia, Anushka, et al.
Publicado: (2023)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Posttreatment Attrition and Its Predictors, Attrition Bias, and Treatment Efficacy of the Anxiety Online Programs
por: AL-Asadi, Ali M, et al.
Publicado: (2014)

Reducing Resident Physician Workload to Improve Well Being
por: Al-kofahi, Mejalli, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n8ahfprlcsneh61cn13ev95sg2